Comparative Study on Usability of Inhaler Devices in Adults With Asthma or COPD

NACompletedINTERVENTIONAL
Enrollment

84

Participants

Timeline

Start Date

April 30, 2016

Primary Completion Date

December 31, 2017

Study Completion Date

January 31, 2018

Conditions
AsthmaCOPD
Interventions
DEVICE

Spiromax (budesonide/formoterol)

"DuoResp Spiromax 160 (160 micrograms budesonide/4.5 micrograms formoterol fumarate dihydrate), either one inhalation twice a day (morning and evening) or two inhalations twice a day (morning and evening), for 1 week.~Additional 8 weeks in one subgroup"

DEVICE

Turbohaler (budesonide/formoterol)

Turbohaler® (160 micrograms budesonide/4.5 micrograms formoterol fumarate dihydrate)- Symbicort® 160/4.5. Dose of one inhalation twice a day (mornig and evening) or two inhalations twice a day (morning and evening), for 1 week. Additional 8 weeks in one subgroup

DEVICE

Diskus(50mcg salmeterol &250/500 mcg fluticasone propionate)

Diskus® inhaler(50mcg salmeterol\&250/500mcg fluticasone propionate)-Seretide Diskus 50/250mcg® or 50/500mcg.Dose of 1inhalation twice a day for1 week.Additional 8 weeks in1subgroup

Trial Locations (3)

21049

4) Clinica di Malattie dall'Apparato Respiratorio Fondazione Salvatore Maugeri, Tradate

44124

University Hospital S Anna, Ferrara

70020

3) Fondazione S. Maugeri - IRCCS - Dipartimento di Pneumologia Riabilitativa, Cassano delle Murge

All Listed Sponsors
lead

Consorzio Futuro in Ricerca

OTHER

NCT02757209 - Comparative Study on Usability of Inhaler Devices in Adults With Asthma or COPD | Biotech Hunter | Biotech Hunter